Members of the DOM contributed to a landmark international consensus report about precision diabetes medicine. Two hundred academic experts from 28 countries took part in this report under the banner of the Precision Medicine in Diabetes Initiative. It was supported by the American Diabetes Association, the European Association for the Study of Diabetes and the Novo Nordisk Foundation.
The report shows clear progress in implementing precision diabetes medicine, illuminating opportunities for its immediate or near-term clinical application. For example, precision medicine was shown to play an essential role in diagnosing and treating monogenic diabetes, as well as great potential in managing gestational diabetes. The report also shed light on numerous research gaps and the need for improved research methods.
Dr. Nestoras Mathioudakis, associate professor in the Division of Endocrinology, Diabetes & Metabolism and co-medical director of the Johns Hopkins Medicine Diabetes Prevention & Education Program, served as the co-chair of the Precision Prognostics for Cardiovascular Disease writing group in type 2 diabetes. Other members of Hopkins involved in the report include (members of the DOM are in bold):
- Daisy Duan, assistant professor in the Division of Endocrinology, Diabetes & Metabolism
- Bige Ozkan, fellow in the Division of Cardiology
- Scott Pilla, assistant professor in the Division of General Internal Medicine
- Debashree Ray, assistant professor, School of Public Health
- Mary Rooney, assistant professor, School of Public Health
- Sudipa Sarkar, assistant professor, in the Division of Endocrinology, Diabetes & Metabolism and director of the Inpatient Diabetes Management Service
- Elizabeth Selvin, joint appointment in the Division of General Internal Medicine
- Amelia S. Wallace, research assistant, School of Public Health
- Caroline Wang, research program coordinator, School of Public Health
Read the report published in Nature Medicine here.
Read the press release from the Novo Nordisk Foundation here.
